Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …

The three-signal paradigm tries to capture how the innate immune system instructs adaptive
immune responses in three well-defined actions:(1) presentation of antigenic peptides in the …

While chemotherapy delivery by nanocarriers has modestly improved the survival prospects
of pancreatic ductal adenocarcinoma (PDAC), additional engagement of the immune …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Pancreatic ductal adenocarcinoma (PDA), the most frequent type of pancreatic cancer,
remains one of the most challenging problems for the biomedical and clinical fields, with …

Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a
significant need for improved therapeutic options. While the recent breakthroughs of …

Pancreatic ductal adenocarcinomas (PDAs) erect physical barriers to chemotherapy and
induce multiple mechanisms of immune suppression, creating a sanctuary for unimpeded …

Pancreatic cancer is one of the most malignant tumors with increased incidence rate. The
effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory …

Purpose: Local tumor ablation through irreversible electroporation (IRE) may offer a novel
therapeutic option for locally advanced pancreatic cancer (LAPC). It may also serve as a …

Pancreatic cancer is considered to be one of the most aggressive cancers. For unknown
reasons, the incidence of pancreatic cancer is slowly rising and so too are mortality rates …